Kinase Inhibitors Market
Number of pages: 100 | Report Format: PDF | Published date: March 20, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 54.1 billion |
|
Revenue Forecast in 2031 |
US$ 93.0 billion |
|
CAGR |
6.2% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023-2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Type, Application, Distribution Channel, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global kinase inhibitors market was valued at US$ 54.1 billion in 2022 and is expected to register a revenue CAGR of 6.2% to reach US$ 93.0 billion by 2031.
Kinase Inhibitors Market Fundamentals
Kinase inhibitors are the agents that inhibit the kinase enzyme family. Many kinases are present in human cells, which aid in regulating vital processes, such as cell signaling, metabolism, division, and survival. In some types of cancer cells, specific kinases are highly active, and inhibiting these kinases may help prevent the cancer cells from proliferating. Many biological processes, such as cell division, proliferation, and death, depend on kinases. A cell may perish or perform badly if kinases are blocked. Kinase inhibitors may also prevent cancers from growing new blood vessels, which they require to do so. Inhibitors of some kinases are used to treat cancer. Protein kinases have a role in several biological processes, including differentiation, cell survival, and cell cycle regulation.
Protein kinase dysregulation is linked to several cancer pathways. The introduction of protein kinase inhibitors in cancer therapy has brought about paradigm shifts in treating cancer. The FDA has approved several protein kinase inhibitors in the past few decades. The likelihood that kinase inhibitors would be effective depends on the level of oncogenic addiction to the particular kinase and the pharmacokinetic and pharmacological characteristics of the kinase inhibitor.
There are 538 protein kinases in the human genome that transfer phosphate from ATP to serine, threonine, or tyrosine residues. Several of these kinases are linked to the development and spread of human cancer. Clinical therapy has been successful in the recent development of small-molecule kinase inhibitors for the treatment of various forms of cancer. Notably, protein kinases placed high among therapeutic targets after G-protein-coupled receptors in drug targeting. The FDA has approved 37 protein kinase inhibitors for treating cancers, such as breast and lung cancer since the first one was created in the early 1980s. Moreover, several kinase-specific inhibitors exist in the preclinical stage of therapeutic research, and about 150 kinase-targeted medications are currently undergoing clinical phase studies.
[7896]
Kinase Inhibitors Market Dynamics
The global kinase inhibitors market is expanding due to the increased incidence of cancer and other chronic diseases, improved cancer diagnosis techniques, and the number of clinical trials for cancer treatment. The number of new cancer types cases has increased over the past few decades. Africa, Asia, Central America, and South America account for more than 60% of all new cancer diagnoses worldwide and are responsible for 70% of all cancer-related deaths. The World Health Organization (WHO) estimates that cancer accounts for 8.3 million annual deaths and that over the next 20 years, there will likely be 70% more new cancer cases reported. Also, technological developments in the pharmaceutical industry and rising R&D spending for cancer therapy by pharmaceutical companies are helping the market grow. To demonstrate the potential of kinase inhibitors as therapeutic agents, companies in the industry are working with researchers to conduct single-arm clinical trials. Companies are working with biotechnology start-ups that can use artificial intelligence to combine target identification and small molecule development. New prospects are, therefore, the most crucial element driving growth.
However, high development costs, strict regulatory constraints, and the introduction of alternative therapies are some of the obstacles the market must overcome. Nonetheless, prospects for the future development of novel and more efficient kinase inhibitors are anticipated, given the rising need for personalized medicine and targeted medicines.
Kinase Inhibitors Market Ecosystem
The global kinase inhibitors market is analyzed from four perspectives: type, application, distribution channel, and region.
Kinase Inhibitors Market by Type
Based on the type, the global kinase inhibitors market is segmented into tyrosine kinase inhibitors, multi-kinase inhibitors, mTOR kinase inhibitors, serine/threonine kinase inhibitors, protein kinase inhibitors, and others.
The tyrosine kinase inhibitors segment accounted for the largest revenue share in 2022. Tyrosine kinases are involved in various cellular processes, such as cell signaling, growth, and division. Blocking these enzymes may aid in preventing the growth of cancer cells since they may be overactive or abundant in particular types of cancer cells. To treat cancer, certain tyrosine kinase inhibitors are employed. They represent a form of targeted therapy. Different types of tyrosine kinase enzymes are receptor tyrosine kinases and non-receptor tyrosine kinases, a small subset of dual-specificity kinases enzymes that can phosphorylate serine, threonine, and tyrosine residues. Tyrosine kinases have become important targets for drug discovery due to their involvement in the development and progression of tumors. Tyrosine kinase inhibitors prevent the appropriate kinases from phosphorylating tyrosine residues on their substrates, preventing the activation of signaling cascades downstream. The development of numerous powerful and well-tolerated tyrosine kinase inhibitors over the past 20 years, including those that target the EGFR, ALK, ROS1, HER2, NTRK, VEGFR, RET, MET, MEK, FGFR, PDGFR, and KIT, has aided in the realization of precision cancer treatment based on the unique genetic alteration features of each patient.
Kinase Inhibitors Market by Application
[95655]
Based on the application, the global kinase inhibitors market is segmented into oncology, inflammatory diseases, and others. The oncology segment is further sub-segmented into lung cancer, renal cell cancer, breast cancer, and others.
The oncology segment accounted for the largest revenue share of the global kinase inhibitors market in 2022. Globally, there were 17.0 million new instances of cancer and 9.5 million cancer-related deaths in 2018, according to estimates from the International Agency for Research on Cancer. Due to population expansion and aging, it is anticipated that by 2040 there will be 16.3 million cancer deaths and 27.5 million new cancer cases worldwide. In the United States, the most prevalent cancers are breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, melanoma of the skin, bladder cancer, non-Hodgkin lymphoma, kidney and renal pelvis cancer, endometrial cancer, leukemia, pancreatic cancer, thyroid cancer, and liver cancer (listed in descending order by estimated new cases in 2020). Due to the rising frequency of risk factors such as smoking, poor diet, lack of physical activity, and fewer pregnancies in economically developing nations, the burden will likely grow. Nowadays, targeted therapy for treating different tumors uses kinase inhibitors licensed by the FDA for their increased therapeutic advantages. About 8 of the 62 FDA-approved medicinal drugs that target various protein kinases were authorized in 2020. Kinase inhibitors are being employed as FDA-approved cancer treatments, and newly created ones are being tested in clinical studies. Growth factor receptor inhibitors, Ras/Raf/MEK inhibitors, phosphoinositide 3-kinase (PI3K), cyclin-dependent kinase inhibitors, additional targets, and medications such as protein kinase c and 3 phosphoinositide-dependent kinases can all be lumped together as protein kinase inhibitors.
Kinase Inhibitors Market by Distribution Channel
Based on the distribution channel, the global kinase inhibitors market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
The hospital pharmacies segment accounted for the largest revenue share of the global kinase inhibitors market in 2022. Hospital pharmacies play a critical role in maximizing patient care by collaborating with doctors, nurses, and other healthcare workers to supply the right medications and supplies by established treatment procedures. A nationwide survey of hospital pharmacy procedures was carried out by the American Society of Health-System Pharmacists. The findings demonstrate that hospital pharmacists provide better patient care and continuously provide more medication-related interventions for patient transitions. The hospital pharmacy significantly impacts the economics of healthcare expenses. The rate of hospital admission and the number of outpatients are increasing due to the rising incidence of cancer and other inflammatory disorders. Thus, hospitals play a significant role in creating better treatments for various cancer-related issues. As a result, hospital pharmacies that provide immediate therapy for acromegaly have seen a large increase in sales. Additionally, various government programs, including the subsidized medicine program, assist patients in purchasing pricey therapies for uncommon ailments regardless of their financial circumstances. Due to rising prescription costs and the dearth of pharmaceuticals in retail pharmacies, people now prefer hospital pharmacies, which has significantly increased revenue. For instance, The Ministry of Health and Family Welfare, Government of India, provides financial assistance in cases without free medical facilities. Patients with annual family incomes of up to Rs. 1,25,000 and below are eligible for financial support ranging from Rs. 75,000 to Rs. 1,25,000 under the Health Minister’s Discretionary Grant program to cover a portion of the cost of cancer treatment in government hospitals.
Kinase Inhibitors Market by Region
Based on the region, the global kinase inhibitors market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America accounted for the largest revenue share of the global kinase inhibitors market in 2022. Throughout the forecast period, North America is projected to keep this position in terms of revenue. This can be attributed to strong and developed economies, such as the United States and Canada, and an increase in investments in R&D activities for developing novel cancer treatments. The kinase inhibitors market is also growing significantly due to the presence of top pharmaceutical companies in the country. One of the highest cancer rates in the world is in the United States, which is anticipated to spur market expansion.
Kinase Inhibitors Market Competitive Landscape
The kinase inhibitors market has a moderately competitive landscape due to new product introductions, mergers, and acquisitions. Launching novel therapeutics, obtaining approval for those products, and participating in other activities like awareness programs are key development strategies that many organizations emphasize. Additionally, the market classified partnerships, acquisitions, and collaborations as improved growth strategies. Given the rising global market demand for kinase inhibitors, these steps have increased the likelihood of having profitable growth prospects in the future.
The notable market participants include:
Kinase Inhibitors Market Strategic Developments
A kinase inhibitor is a drug that blocks the family of kinase enzymes. Human cells include many kinases, which help control critical functions, such as cell signaling, metabolism, division, and survival. Certain kinases are very active in some types of cancer cells, and blocking these kinases may help stop the cancer cells from reproducing. The development of new blood vessels, which tumors need to spread, may also be prevented by kinase inhibitors. Cancer is treated with kinase inhibitors in some cases.
New treatment strategies and increased disease prevalence of several chronic diseases and cancer are the key trends fueling global kinase Inhibitors market revenue growth.
Severe side effects and a lack of awareness about kinase inhibitors are potentially restricting the revenue growth of the global market.
Key companies operating the global kinase inhibitors market are Novartis AG, Pfizer, Inc., Bristol-Myers Squibb Company, Merck & Co., Inc., and F. Hoffmann-La Roche Ltd.
The global kinase inhibitors market is expected to grow at a revenue CAGR of 6.2% during the forecast period from 2023 to 2031.
*Insights on financial performance are subject to the availability of information in the public domain